A detailed history of Bridgefront Capital, LLC transactions in Regeneron Pharmaceuticals, Inc. stock. As of the latest transaction made, Bridgefront Capital, LLC holds 391 shares of REGN stock, worth $263,135. This represents 0.17% of its overall portfolio holdings.

Number of Shares
391
Holding current value
$263,135
% of portfolio
0.17%

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$1024.09 - $1201.76 $400,419 - $469,888
391 New
391 $411,000
Q2 2023

Aug 14, 2023

BUY
$700.03 - $830.35 $377,316 - $447,558
539 New
539 $387,000
Q3 2021

Nov 12, 2021

SELL
$574.03 - $680.96 $981,591 - $1.16 Million
-1,710 Closed
0 $0
Q2 2021

Aug 12, 2021

SELL
$472.8 - $558.54 $52,008 - $61,439
-110 Reduced 6.04%
1,710 $955,000
Q1 2021

May 17, 2021

BUY
$446.73 - $548.2 $146,080 - $179,261
327 Added 21.9%
1,820 $861,000
Q4 2020

Feb 12, 2021

BUY
$478.3 - $607.98 $714,101 - $907,714
1,493 New
1,493 $721,000

Others Institutions Holding REGN

About REGENERON PHARMACEUTICALS, INC.


  • Ticker REGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 107,190,000
  • Market Cap $72.1B
  • Description
  • Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macula...
More about REGN
Track This Portfolio

Track Bridgefront Capital, LLC Portfolio

Follow Bridgefront Capital, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bridgefront Capital, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Bridgefront Capital, LLC with notifications on news.